A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.22.14_SUPPL.5054PMID 28015527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Biological Activity of Resveratrol on an Ovarian Cancer Cell

  2014cites this paper
• An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2

  2010cites this paper
• Targeted Therapies in Epithelial Ovarian Cancer

  2010cites this paper
• A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

  2008cites this paper
• Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor

  2008cites this paper
• The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

  2007cites this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cites this paper
• Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

  2007cites this paper
• Molecular Targeted Therapies in the Treatment of Ovarian Cancer

  2007cites this paper
• Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

  2006cites this paper
• Novel therapeutic agents in ovarian cancer.

  2006cites this paper
• Biological characterization of ovarian cancer: prognostic and therapeutic implications.

  2005cites this paper
• Emerging drugs for ovarian cancer

  2005cites this paper
• Investigational agents for epithelial ovarian cancer

  2005cites this paper
• Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

  2005cites this paper
• Integration of new or experimental treatment options and new approaches to clinical trials.

  2005cites this paper
• Emerging drugs for ovarian cancer

  2005cites this paper
• Therapeutic targeting of receptor tyrosine kinases in lung cancer

  2005cites this paper
• Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer

  2005cites this paper
• Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.

  2005cites this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cites this paper